EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Therapeutic Potential of Melatonin in Gastrointestinal Cancers: Molecular Mechanisms, Preclinical Evidence and Clinical Implications

Maciej Gonciarz, Benita Wiatrak, Iga Lombard, Łukasz Konecki, Joanna Sarbinowska

Journal of Pineal Research · 2026-01 · 78 (1)

DOI: 10.1111/jpi.70101 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Gastrointestinal (GI) cancers remain a leading cause of global morbidity and mortality, necessitating novel therapeutic strategies. Melatonin (MEL), an indoleamine with pleiotropic biological activities, has emerged as a promising adjuvant in oncology due to its antiproliferative, proapoptotic, and antioxidant properties. This review synthesizes current evidence on MEL's molecular mechanisms in GI carcinogenesis, including modulation of NF‐κB, PI3K/AKT, and Wnt/β‐catenin pathways, suppression of reactive oxygen species (ROS), and regulation of circadian rhythm‐related genes (e.g., CLOCK, BMAL1). Preclinical studies demonstrate that MEL enhances chemoradiotherapy efficacy‐reducing tumor volume by 70% in murine colorectal models and decreasing 5‐fluorouracil (5‐FU) resistance via miR‐532‐3p/β‐catenin axis modulation. Clinical trials report a 23%–41% risk reduction in colorectal cancer among shift workers with MEL supplementation and a 53% decrease in radiotherapy‐induced oral mucositis. Despite promising data, limitations persist: fewer than 15% of clinical trials focus on GI cancers, dosing remains unstandardized (10–40 mg/day), and molecular heterogeneity (e.g., KRAS mutations in pancreatic cancer) may limit therapeutic responses. Future research must prioritize phase III trials, chronotherapy optimization, and biomarker‐driven approaches, including MT1/MT2 receptor expression and microbiome profiling. Given its low toxicity and putative synergy with immunotherapies, MEL should be regarded as an adjunct under investigation rather than an established option; to date, no GI‐specific phase III randomized trials exist, and clinical signals come primarily from small, heterogeneous cohorts. Dosing is unstandardized and limited by low oral bioavailability (first‐pass) and possible pharmacogenomic variability.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →